1106TiPHope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing SGC
Locati, L.D., Caballero, C., Fortpied, C., Perrone, F., Pilotti, S., Harrington, K.J., Grégoire, V., Licitra, L.Volume:
28
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx374.057
Date:
September, 2017
File:
PDF, 93 KB
2017